sïParadigm Announces Participation in NCI's ComboMATCH Initiative
sïParadigm is proud to announce its selection as a Designated Laboratory for National Cancer Institute (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice. This groundbreaking precision medicine study aims to evaluate effectiveness of new drug combinations for patients with advanced solid tumors based on unique genetic makeup of their tumors.
Read Full Press Release

